New Study Evaluates Cost-Effectiveness of Cholesterol Screening for Kids

A study conducted by researchers at Columbia University and Harvard University has raised important questions about the cost-effectiveness of screening children for genetic predispositions to high cholesterol. The research, published in JAMA on November 9, 2023, highlights the potential benefits of early detection in preventing serious health issues, while also addressing the financial implications of such screening programs.

In the United States, approximately 1 in every 250 individuals has a genetic variant known as familial hypercholesterolemia (FH), which can lead to dangerously high cholesterol levels from birth. If left untreated, those with FH face a significantly increased risk of heart attacks or strokes starting as early as their 30s or 40s. Alarmingly, nearly 90% of the estimated 1.5 million Americans with this condition are unaware of their health status.

Andrew Moran, an associate professor of medicine at Columbia University’s Vagelos College of Physicians and Surgeons, emphasizes the importance of early intervention: “Early recognition and management of high cholesterol, even in childhood, can prevent or delay heart attacks, strokes, and maybe even dementia later in life.” The study suggests the need for a cost-effective approach to screening for FH, particularly for children and young adults.

Screening Strategies and Their Implications

The study evaluated various scenarios involving a two-stage screening process. This approach would first assess children’s cholesterol levels (specifically low-density lipoprotein cholesterol, LDL-C) and then conduct genetic testing for FH in individuals with elevated cholesterol. Researchers aimed to determine whether screening at age 10 or age 18 could significantly reduce the incidence of heart disease later in life.

The findings indicate that while FH is one of the more common genetic disorders, its overall prevalence makes widespread screening financially challenging. The model revealed that conventional cholesterol and genetic screening strategies were not cost-effective when compared to standard care. Instead, the study suggests that if cholesterol screening leads to more rigorous management of all children and young adults with high cholesterol—regardless of genetic testing results—screening at age 18 would be the most economically viable option.

Currently, one in five adolescents presents abnormalities in standard lipid screenings. The American Academy of Pediatrics and the American Heart Association recommend that all children have their cholesterol measured between the ages of 9 and 11. Yet, less than 20% of children actually receive this critical testing.

Future Directions and Newborn Screening Potential

Looking ahead, the researchers propose that integrating FH screening with established childhood screening protocols, such as newborn screening, may enhance cost-effectiveness. Recent studies have shown the feasibility of pairing cholesterol and genetic screening for FH using blood spots collected during newborn screenings. This innovative approach could streamline the process and improve early detection rates.

Moran notes that an additional advantage of conducting childhood genetic testing for FH is the opportunity for cascade screening and treatment among family members who may also be affected but remain undiagnosed. This aspect, however, was not fully accounted for in the current model.

As research continues, Moran asserts, “We haven’t landed on the best way to screen early for FH yet, but with our modeling, we’re leveraging the best evidence and efficient computer modeling methods to arrive at the most promising approaches to test in real clinical trials of screening.”

The implications of this study are significant, especially for public health policies aimed at reducing cardiovascular disease risk among future generations. By exploring cost-effective screening strategies, researchers aim to pave the way for improved health outcomes for children and young adults at risk of high cholesterol and related conditions.